Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Astellas will acquire Agensys for $387 million in cash, net of Agensys' $30 million in cash.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury